Articles

Novel agent iberdomide demonstrated clinically meaningful activity and was generally well tolerated in a multicohort phase 1/2 trial. Read More ›

Meta-analysis suggests that lenalidomide-carfilzomib may be the most effective maintenance treatment in patients with newly diagnosed multiple myeloma. Read More ›

In the first trial with this treatment regimen, quadruplet induction with Isa-KRd in patients with high-risk MM demonstrated promising activity and a tolerable safety profile. Read More ›

Implementation of a pharmacist on the healthcare team can have significant clinical and economic benefits. Read More ›

Updated results from a phase 1 trial of subcutaneous isatuximab via OBDS continue to demonstrate an excellent local tolerability with comparable efficacy. Read More ›

Preliminary data support the use of BMS-986393 in patients with RRMM despite prior BCMA-directed therapy. Read More ›

Data from a subgroup analysis of CANDOR supported the efficacy of daratumumab plus carfilzomib and dexamethasone in RRMM, even in high-risk patients. Read More ›

A phase 1 trial of GC012F demonstrated an overall response rate of 100% in high-risk, transplant-eligible patients with newly diagnosed multiple myeloma. Read More ›

A head-to-head phase 3 clinical trial in patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) has found that zanubrutinib (Brukinsa), a next-generation Bruton tyrosine kinase (BTK) inhibitor, was more effective at preventing disease progression and is better tolerated than ibrutinib (Imbruvica), a first-generation BTK inhibitor that is the current standard of care for this population of patients. Read More ›

The use of low-molecular-weight heparin (LMWH) did not improve the rate of live births among pregnant women with inherited thrombophilia and recurrent miscarriage, according to results of a clinical trial presented during the 64th American Society of Hematology Annual Meeting and Exposition. Read More ›